TICKERNERD
Menu
DNTHDNTHHealthcare · Biotechnology

DNTH Stock Forecast: Dianthus Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 14 Sept 2026
$108
+1.40% on the day

The 16 Wall Street analysts covering Dianthus Therapeutics, Inc. hold a median 12-month price target of $134 — +24.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 61 of 100 as at 14 Sept 2026 — in the upper half.

Market cap
$5.9B
Ticker Nerd rank
61 / 100
Median analyst target
$134
Analysts covering
16
Revenue$761K+294.3% y/y
Operating income−$61.5M
Net income−$50.2M
Free cash flow−$49.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.4%
1M
−7.1%
YTD
+161.3%
1Y
+189.8%
From 52W high
−7.1%
From 52W low
+227.1%
$33
$116
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

DNTH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Dianthus Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Sept 2026
61 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
100
Volatility
85
Quality
79
Value
76
Revisions
65
Growth
32
Accruals
29
Issuance
27
Size
21

Momentum (100): The shares have been drifting up relative to others.

Issuance (27): The company has been issuing shares or taking on financing, diluting existing holders.

Size (21): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

DNTH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DNTH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$100$150$200Oct 25Jan 26Apr 26Jul 26DNTHHigh $200Median $134Low $122

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says16 analysts
16 Buy0 Hold0 Sell
Low $122Median $134High $200

The green dot is the last close — the median target sits +24.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
11 Sept 2026JP MorganInitiatesOverweight$135
4 Sept 2026CitigroupInitiatesBuy$156
6 Aug 2026HC Wainwright & Co.MaintainsBuy—
6 Aug 2026HC Wainwright & Co.MaintainsBuy$130 → $158
6 Aug 2026Truist SecuritiesMaintainsBuy—
6 Aug 2026Truist SecuritiesMaintainsBuy$110 → $128
5 Aug 2026WedbushMaintainsOutperform$105 → $122
5 Aug 2026WedbushMaintainsOutperform—
3 Aug 2026Evercore ISI GroupMaintainsOutperform$120 → $134
3 Aug 2026Evercore ISI GroupMaintainsOutperform—
6 May 2026WedbushMaintainsOutperform—
6 May 2026WedbushMaintainsOutperform$103 → $105
9 Apr 2026Wolfe ResearchInitiatesOutperform—
19 Mar 2026Wells FargoInitiatesOverweight—
12 Mar 2026WedbushMaintainsOutperform—
10 Mar 2026BairdMaintainsOutperform—
10 Mar 2026Clear StreetMaintainsBuy—
10 Mar 2026Raymond JamesUpgradeStrong Buy—
10 Mar 2026WedbushMaintainsOutperform—
9 Mar 2026HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DNTH appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

DNTH vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Sept 2026, Dianthus Therapeutics, Inc. returned +189.8% against +17.0% for the S&P 500, dividends included.

DNTH vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Oct 25Jan 26Apr 26Jul 26DNTHS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

DNTH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
1
Fundamentals

Dianthus Therapeutics, Inc. (DNTH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
3.3×

Cheaper than 68% of US stocks

Price / sales
3201.7×

Cheaper than 1% of US stocks

Price / book
5.1×

Cheaper than 20% of US stocks

EV / EBITDA
−23.2×

Cheaper than 90% of US stocks

Growth & margins
Revenue growth (YoY)
294.3%

Higher than 97% of US stocks

Earnings growth (YoY)
294.3%

Higher than 93% of US stocks

Gross margin
—
Operating margin
−8079.1%

Higher than 2% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−26.1%

Higher than 29% of US stocks

Return on assets
−17.7%

Higher than 21% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Dianthus Therapeutics, Inc. (DNTH) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Dianthus Therapeutics, Inc. has a market value of $5.9B and an enterprise value of $5.1B.

  • Revenue in the twelve months to 30 June 2026: $1.9M. The latest quarter grew 294.3% year on year.

  • Net income over the same four quarters: −$192.2M, a −10097.0% net margin.

  • Diluted earnings per share, trailing twelve months: $−4.15.

  • Free cash flow in the twelve months to 30 June 2026: −$155.7M, after $334K of capital spending.

  • Shares outstanding: 54.8M.

  • Trailing P/E: 3.3×; forward P/E: −23.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Dianthus Therapeutics, Inc. employs 92 people — $21K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 15 Sept 2026

Data provided by Twelve Data

Peers

DNTH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
DNTHDianthus Therapeutics, Inc.$5.9B
61
COGTCogent Biosciences, Inc.$5.7B
36
XENEXenon Pharmaceuticals, Inc.$5.6B
50
TVTXTravere Therapeutics, Inc.$6.2B
87
ERASErasca, Inc.$5.5B
57
LGNDLigand Pharmaceuticals, Inc.$5.5B
72
PTCTPTC Therapeutics, Inc.$5.5B
64

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Dianthus Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest DNTH news & analysis

Dianthus Therapeutics, Inc. (DNTH) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Seeking Alpha · 9 Sept 2026neutral

Dianthus Therapeutics, Inc. (DNTH) presented at Citigroup's Biopharma Back to School Summit 2026, with the event transcript published by Seeking Alpha. The item reports on the company's participation in the conference presentation.

Why it matters — DNTH watchers would follow this conference appearance for insights shared by management during the presentation.

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 2 Sept 2026neutral

Dianthus Therapeutics granted equity awards on September 1, 2026, to four newly-hired, non-executive employees as material inducements to accept employment. The grants were approved by the company's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

Why it matters — DNTH watchers would note the company is hiring new staff supported by incentive compensation, signaling workforce growth without conveying strategic or financial information.

Dianthus Therapeutics to Participate in Three Investor Conferences During September

GlobeNewsWire · 1 Sept 2026neutral

Dianthus Therapeutics, a clinical-stage biotechnology company focused on next-generation therapies for severe autoimmune diseases, announced it will participate in three investor conferences during September. The announcement was made on September 1, 2026, via GlobeNewsWire.

Why it matters — Dianthus watchers may gain updates on the company's development progress and outlook through its presentations at these investor conferences.

Dianthus Therapeutics: The C1s Shakeout Strengthens The Bull Case

Seeking Alpha · 25 Aug 2026positive

Seeking Alpha discusses Dianthus Therapeutics' neuromuscular franchise centered on claseprubart, highlighting its ~$1.2B cash position, financial independence, and reduced funding risk through 2030. The article notes claseprubart's dosing convenience, pathway selectivity, and strong early data differentiate it as competitive dynamics shift following Sanofi's setback.

Why it matters — A DNTH watcher would care because the article argues that Sanofi's setback strengthens the bull case for Dianthus, with its strong cash position and differentiated class prubart profile positioning the company well amid evolving neuromuscular competition.

Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research · 4 Aug 2026positive

Dianthus Therapeutics reported a Q2 loss of $0.90 per share, narrower than the Zacks Consensus Estimate of a $0.93 loss, compared with a $0.88 loss a year earlier. The company also topped revenue estimates for the quarter.

Why it matters — A DNTH watcher would care because the quarterly results came in better than analyst expectations on both loss per share and revenue.

FAQ

Frequently asked questions about DNTH stock

What is the DNTH stock price forecast for 2026-2027?

The 16 Wall Street analysts covering Dianthus Therapeutics, Inc. have a median 12-month price target of $134, with estimates ranging from $122 to $200. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DNTH stock a buy right now?

Of the 16 analysts covering Dianthus Therapeutics, Inc., 16 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Dianthus Therapeutics, Inc. 61 out of 100 across roughly 4,600 US stocks as at 14 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DNTH?

As at 14 Sept 2026, Dianthus Therapeutics, Inc. ranks 61 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (100 of 100).

Will DNTH stock go up?

No one can know that. What the data says: the median 12-month target from 16 analysts implies +24.4% from the last close, and Ticker Nerd's factor model ranks Dianthus Therapeutics, Inc. 61 out of 100 as at 14 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DNTH stock forecast for 2030?

No analyst covering Dianthus Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DNTH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $122 to $200 over the next 12 months.

How has DNTH stock performed over the past year?

Dianthus Therapeutics, Inc. returned +189.8% over the 12 months to 14 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Dianthus Therapeutics, Inc. do?

Dianthus Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory diseases.

What is the latest news on DNTH?

The most recent item we track (Seeking Alpha, 9 Sept 2026): "Dianthus Therapeutics, Inc. (DNTH) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript". Dianthus Therapeutics, Inc. (DNTH) presented at Citigroup's Biopharma Back to School Summit 2026, with the event transcript published by Seeking Alpha. The item reports on the company's participation in the conference presentation.

Company

About Dianthus Therapeutics, Inc.

Dianthus Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory diseases. The company is centered on complement-targeting science, with a portfolio of monoclonal antibodies and fusion proteins designed to selectively modulate immune pathways involved in disease activity. Its lead programs include claseprubart, an engineered antibody designed to inhibit the active C1s complement protein, and DNTH212, a bifunctional fusion protein that combines immune-cell targeting with suppression of B-cell signaling. Dianthus Therapeutics Inc. is advancing these candidates for conditions such as generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy. The company’s role in the market is to develop differentiated antibody-based treatments aimed at patients with serious immune-mediated disorders that have limited therapeutic options.

CEO Mr. Marino Garcia M.B.A. · 92 employees · United States · https://dianthustx.com